Based on LEADER, what does the typical T2D patient look like who could possibly benefit from CV risk reduction associated with GLP-1 RA therapy? What doses of liraglutide appear to be optimal?

Based on LEADER, what does the typical T2D patient look like who could possibly benefit from CV risk reduction associated with GLP-1 RA therapy? What doses of liraglutide appear to be optimal?

Based on LEADER, what does the typical patient with T2D look like who could possibly benefit from CV risk reduction associated with GLP-1 RA therapy? What doses of liraglutide would appear to be optimal?

CLICK HERE FOR CME CREDIT

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

John Petrie, MD, PhD

John Petrie, MD, PhD

Professor of Diabetic Medicine
University of Glasgow
Honorary Consultant Physician and Diabetologist
Glasgow Royal Infirmary and Stobhill Hospital
Glasgow, Scotland